This study compares two medications, pramipexole and escitalopram, to treat Major Depressive Disorder (MDD) and mild neurocognitive disorder (MND) in people with HIV. HIV is a virus that attacks the immune system. MDD is a condition causing persistent sadness, while MND involves mild memory and thinking problems. Pramipexole and escitalopram are types of antidepressant drugs.

The trial is open-label, meaning both the participants and the researchers know which medication is being given. Participants will be monitored for safety and effectiveness. Some participants may also join a sub-study to see how the treatment affects the cerebrospinal fluid (CSF), a fluid around the brain and spinal cord.

• The study will have several visits, with checks for side effects and treatment response.
• Participants must have been on HIV treatment for at least 3 months.
• People with certain health conditions or who are pregnant cannot join the study.